|
| 37088457 | Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study. | Clin Gastroenterol Hepatol | 2024 |
| 37088458 | Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study. | Clin Gastroenterol Hepatol | 2024 |
| 35074532 | Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials. | Clin Gastroenterol Hepatol | 2023 |
| 37024212 | Role of Liver Biopsy in Clinical Trials and Clinical Management of Nonalcoholic Fatty Liver Disease. | Clin Liver Dis | 2023 |
| 36967586 | The combination of the enhanced liver fibrosis and FIB-4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease. | Aliment Pharmacol Ther | 2023 |
| 36922785 | PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis. | BMC Gastroenterol | 2023 |
| 36750244 | Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. | Gut | 2023 |
| 36647687 | Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis. | Aliment Pharmacol Ther | 2023 |
| 36797481 | Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial. | Nat Med | 2023 |
| 34662449 | Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. | Hepatology | 2022 |
| 35384259 | An MMP-degraded and cross-linked fragment of type III collagen as a non-invasive biomarker of hepatic fibrosis resolution. | Liver Int | 2022 |
| 35090960 | Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. | J Hepatol | 2022 |
| 35194091 | Protein and miRNA profile of circulating extracellular vesicles in patients with primary sclerosing cholangitis. | Sci Rep | 2022 |
| 34793868 | Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. | J Hepatol | 2022 |
| 34605045 | BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial. | Hepatology | 2022 |
| 32544255 | From NAFLD to MAFLD: Implications of a Premature Change in Terminology. | Hepatology | 2021 |
| 33570776 | A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH. | Hepatology | 2021 |
| 33616848 | Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. | Obes Surg | 2021 |
| 33657443 | The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. | Contemp Clin Trials | 2021 |
| 34454994 | Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population. | J Hepatol | 2021 |
| 34333790 | A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis. | Hepatology | 2021 |
| 34278169 | Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. | Hepatol Commun | 2021 |
| 33169409 | Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH. | Hepatology | 2021 |
| 33164276 | Multicenter, Double-Blind, Randomized Trial of Emricasan in Hepatitis C-Treated Liver Transplant Recipients With Residual Fibrosis or Cirrhosis. | Liver Transpl | 2021 |
| 32607686 | Fifty years of impact on liver pathology: a history of the Gnomes. | Virchows Arch | 2021 |
| 32745270 | A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis. | Hepatology | 2021 |
| 32707342 | Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. | Clin Gastroenterol Hepatol | 2021 |
| 32150543 | Association of novel markers of liver disease with neonatal liver disease in premature baboons, Papio sp. | PLoS One | 2020 |
| 31887369 | A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. | J Hepatol | 2020 |
| 31943293 | Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. | Hepatology | 2020 |
| 31881392 | Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. | Contemp Clin Trials | 2020 |
| 33163834 | Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes. | Hepatol Commun | 2020 |
| 33437901 | Major Histocompatibility Complex Class I-Related Chain A Alleles and Histology of Nonalcoholic Fatty Liver Disease. | Hepatol Commun | 2020 |
| 32923831 | Characterization and Proteome of Circulating Extracellular Vesicles as Potential Biomarkers for NASH. | Hepatol Commun | 2020 |
| 30291868 | Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. | J Hepatol | 2019 |
| 31813633 | Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. | Lancet | 2019 |
| 32039401 | Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis. | JHEP Rep | 2019 |
| 30160980 | Assessment of liver fibrosis progression and regression by a serological collagen turnover profile. | Am J Physiol Gastrointest Liver Physiol | 2019 |
| 30153359 | Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. | Hepatology | 2019 |
| 31271665 | Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. | Hepatology | 2019 |
| 31260793 | REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. | Contemp Clin Trials | 2019 |
| 31393374 | Analysis of human leukocyte antigen allele polymorphism in patients with non alcoholic fatty liver disease. | Medicine (Baltimore) | 2019 |
| 30744560 | Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis. | BMC Gastroenterol | 2019 |
| 30993748 | The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. | Hepatology | 2019 |
| 28892558 | The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. | Hepatology | 2018 |
| 30075518 | Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016. | Medicine (Baltimore) | 2018 |
| 29990488 | Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. | Gastroenterology | 2018 |
| 30205811 | An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease. | BMC Med | 2018 |
| 30144554 | The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. | J Hepatol | 2018 |
| 29928018 | Polymorphisms in the receptor for advanced glycation end-products (RAGE) gene and circulating RAGE levels as a susceptibility factor for non-alcoholic steatohepatitis (NASH). | PLoS One | 2018 |